FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
How hot are antibody-drug conjugates?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
GenFleet bids to join the colorectal KRAS crowd
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
Mythic goes back to basics
More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
